Biogen Idec Gets Potential Oral Tysabri Follow-on In UCB Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's second oral multiple sclerosis candidate employs the same mechanism as Tysabri and is set to enter Phase II early next year.